Safety Issue Halts Study of BMS HCV Drug
(MedPage Today) — Bristol-Myers Squibb has suspended treatment “to protect patient safety” in a phase IIb trial of an investigational oral drug for hepatitis C.
(MedPage Today) — Bristol-Myers Squibb has suspended treatment “to protect patient safety” in a phase IIb trial of an investigational oral drug for hepatitis C.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.